J&J Envisions Eye Care, Oral Care Expansions Following Pfizer OTC Purchase
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson will "explore" areas such as gum health, tooth whitening and the treatment of periodontal disease as it works to extend its presence in the oral care market with its acquisition of Pfizer's Listerine mouthwash
You may also be interested in...
Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings
Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings
Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings